Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 9;19(7):e0306860.
doi: 10.1371/journal.pone.0306860. eCollection 2024.

The relationship between complete blood cell count-derived inflammatory biomarkers and benign prostatic hyperplasia in middle-aged and elderly individuals in the United States: Evidence from NHANES 2001-2008

Affiliations

The relationship between complete blood cell count-derived inflammatory biomarkers and benign prostatic hyperplasia in middle-aged and elderly individuals in the United States: Evidence from NHANES 2001-2008

Chengdong Shi et al. PLoS One. .

Abstract

Background: Benign prostatic hyperplasia (BPH) is a common health disorder of the male genitourinary system with a high prevalence, especially among middle-aged and older adults, which seriously affects men's quality of life. Inflammatory markers derived from complete blood cell count (CBC) have previously been considered a prognostic indicator for various diseases, but little is known about their relationship with BPH. This study evaluated the relationship between complete blood cell count (CBC)-derived inflammatory biomarkers and BPH.

Methods: Data for this cross-sectional study were gathered from the National Health and Nutrition Examination Survey (NHANES) between 2001 and 2008. Using multiple logistic regressions, the study examined the association between benign prostatic hyperplasia(BPH) and Inflammatory biomarkers derived from blood cell counts such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), Systemic Inflammatory Response Index (SIRI) and Systemic Immunoinflammatory Index (SII).

Results: 3,919 participants were included, with a median age of 61.00 (52.00-71.00) years old. Among them, 609 participants had benign prostatic hyperplasia, with a prevalence of 15.54%. Upon accounting for confounding factors, the study revealed a positive correlation between the plurality of BPH PLR and SII. However, MLR, NLR, and SIRI did not significantly correlate with the prevalence of BPH (p>0.05). In contrast to the lowest quartile, higher quartiles of PLR (OR = 1.93[1.38-2.69]) and SII (OR = 1.71[1.22-2.40]) were linked to an elevated risk of BPH. Interaction tests showed that age, body mass index, hypertension, diabetes, smoking, and drinking had no significant effect on this positive correlation (p for interaction>0.05). In addition, we found a roughly linear association between SII, PLR, and BPH using smoothed curve fitting.

Conclusions: According to our research, high levels of PLR and SII are positively linked with an increased risk of BPH in middle-aged and elderly individuals in the United States. The results compensate for previous studies that still need to be validated with larger prospective cohorts.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Flowchart of the participant selection from NHANES 2001–2008.
Fig 2
Fig 2. Subgroup analysis for the association between PLR/100 and BPH.
Abbreviations PLR: Platelet-to-lymphocyte Ratio; BPH: Benign Prostatic Hyperplasia.
Fig 3
Fig 3. Subgroup analysis for the association between SII/100 and BPH.
Abbreviations SII: Systemic Immunoinflammatory Index; BPH: Benign Prostatic Hyperplasia.
Fig 4
Fig 4. Association of PLR and SII with BPH.
The solid red line represents the smooth curve fit between variables. The Blue dotted line represents the 95% confidence interval from the fit. Abbreviations PLR: Platelet-to-lymphocyte Ratio; BPH: Benign Prostatic Hyperplasia; SII: Systemic Immunoinflammatory Index.

Similar articles

Cited by

References

    1. McVary K.T., BPH: epidemiology and comorbidities. The American journal of managed care, 2006. 12(5 Suppl): p. S122–8. - PubMed
    1. Sarma A.V. and Wei J.T., Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. The New England journal of medicine, 2012. 367(3): p. 248–57. doi: 10.1056/NEJMcp1106637 - DOI - PubMed
    1. Huang J., et al.., Global burden and temporal trends of lower urinary tract symptoms: a systematic review and meta-analysis. Prostate cancer and prostatic diseases, 2023. 26(2): p. 421–428. doi: 10.1038/s41391-022-00610-w - DOI - PubMed
    1. Kohnen P.W. and Drach G.W., Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study. The Journal of Urology, 1979. 121(6): p. 755–60. doi: 10.1016/s0022-5347(17)56980-3 - DOI - PubMed
    1. Nickel J.C., et al.., Asymptomatic inflammation and infection in benign prostatic hyperplasia. BJU international, 1999. 84(9): p. 976–81. - PubMed